ANI Pharmaceuticals (NASDAQ: ANIP) investors back directors, pay and stock plan
ANI Pharmaceuticals (NASDAQ: ANIP) stockholders approved all proposals at their 2026 Annual Meeting, including the election of seven directors, ratification of Ernst & Young LLP as auditor, and advisory approval of executive compensation. They also approved the Amended and Restated 2022 Stock Incentive Plan and opted for annual advisory votes on executive pay. The meeting's results, detailing voting figures for each proposal, reinforce investor confidence in the company's governance and compensation practices.
ANI Pharmaceuticals Q1 2026 earnings preview
This article is a preview of ANI Pharmaceuticals' first-quarter 2026 earnings. However, the provided content is empty, so no further details about the preview are available.
UBS Group AG Has $11.90 Million Position in ANI Pharmaceuticals, Inc. $ANIP
UBS Group AG significantly reduced its stake in ANI Pharmaceuticals (NASDAQ:ANIP) by 74.4% in Q4, now holding 150,779 shares valued at $11.9 million. Despite this, ANI Pharmaceuticals reported strong Q1 results, with EPS of $2.05 against an expected $1.28 and a 20.5% year-over-year revenue increase to $237.46 million, and reiterated its FY 2026 EPS guidance. Insider selling by SVP Ori Gutwerg and VP Meredith Cook was noted, while analysts maintain a "Moderate Buy" rating with an average price target of $107.33.
ANIP Valuation: Does 9.8x Forward P/E Offer Upside?
ANI Pharmaceuticals (ANIP) is trading at a forward P/E of 9.83x, significantly below its industry, sector, and S&P 500 benchmarks, and its own five-year median. The company's Rare Disease franchise is showing strong momentum, and management has raised its 2026 revenue and EBITDA guidance. Despite underperforming year-to-date against the broader market, its low valuation suggests potential upside if its specialty revenue growth continues and ophthalmology business recovers.
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
ANI Pharmaceuticals is strategically shifting its focus toward Rare Disease and Brands, with Cortrophin Gel and Iluvien driving growth, while generics serve as a cash-flow engine. The company is implementing a 2026 playbook to restore Iluvien's growth after 2025 reimbursement and inventory challenges and expand its specialty presence. Facing intensifying competition and customer concentration risks, ANI aims to meet specific growth targets for Cortrophin and Iluvien, manage generics launches, and navigate margin pressure from royalty-bearing products.
How ANI’s Raised 2026 Guidance And Buyback Plan At ANI Pharmaceuticals (ANIP) Has Changed Its Investment Story
ANI Pharmaceuticals reported strong Q1 2026 results, raising its 2026 revenue guidance to $1.08–$1.14 billion and authorizing a $100 million share repurchase program. This move, combined with the accelerating growth in its Rare Disease segment, particularly Cortrophin Gel, reinforces a narrative of higher margins and earnings per share. However, the company faces risks related to payer and pricing pushback for ACTH therapies and a heavy dependence on a few flagship products.
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
ANI Pharmaceuticals is strategically shifting its focus towards Rare Disease and Brands, with Cortrophin Gel and Iluvien as key growth drivers, while positioning generics as a cash flow engine. The company is actively working to restore Iluvien's growth after 2025 disruptions and plans numerous generic launches for 2026. This repositioning comes with competitive challenges from major players like AbbVie and Regeneron and risks associated with customer concentration.
[144] ANI PHARMACEUTICALS INC SEC Filing
ANI Pharmaceuticals Inc. has filed Form 144 with the SEC, indicating a proposed sale of 10,000 shares of common stock with an aggregate market value of $795,600. The shares were acquired through an open market purchase on March 21, 2022. The filing, dated May 13, 2026, also notes that no securities of the issuer were sold by the person for whose account the securities are to be sold within the past three months.
People moves: Shelly Hubbard joins Lowe’s as ANI Pharmaceuticals brings in Irina Koffler
Shelly Hubbard has been appointed as the new vice president, head of investor relations at Lowe’s, after a tenure at Pentair. Concurrently, ANI Pharmaceuticals announced Irina Koffler as its new vice president, investor relations, transitioning from LifeSci Advisors. Other significant hires include Claire Ross at Colgate-Palmolive, Bill Seymour at James Hardie, Sven Köpsel at Sartorius, and Danah Alomar at Mobily, all taking on key investor relations roles.
ANI Pharmaceuticals(ANIP.US) Officer Sells US$4.27 Million in Common Stock
An officer at ANI Pharmaceuticals (ANIP.US) recently sold a significant amount of common stock, totaling US$4.27 million. This transaction occurred amidst usual market activities and is a noteworthy event for investors tracking insider trading within the company.
ANI Pharmaceuticals director Walsh sells $1.13m in stock
ANI Pharmaceuticals director Patrick D. Walsh sold over $1.13 million in company stock across May 11 and May 13, 2026. Despite the insider sale, ANIP shares have increased by nearly 34% over the past year and recently reported impressive financial results for Q1 2026, surpassing analyst expectations for both EPS and revenue.
Insider Sell: Meredith Cook Sells 500 Shares of ANI Pharmaceuticals Inc (ANIP)
Meredith Cook, Senior Vice President at ANI Pharmaceuticals Inc (ANIP), sold 500 shares of the company on May 13, 2026, bringing her total ownership to 78,390 shares. This transaction is part of a pattern of insider selling, with no insider buys and 49 insider sells over the past year. The stock is currently trading at $78.16, and GuruFocus estimates it to be modestly undervalued with a GF Value of $95.60.
Ani Pharmaceuticals President & CEO Sold Shares Worth Over $4.2M
Ani Pharmaceuticals' President and CEO, Lalwani Nikhil, sold 55,000 shares of common stock at an average price of $77.57 per share, totaling $4,266,350. Following this transaction, Lalwani Nikhil directly holds 349,889 shares of common stock in the company. This information is based on an SEC Form 4 filing.
[Form 4] ANI PHARMACEUTICALS INC Insider Trading Activity
ANI Pharmaceuticals' Senior Vice President, Thomas Andrew Rowland, reported an open-market sale of 459 shares of common stock at $79.21 per share on May 12, 2026. Following this transaction, Rowland directly holds 38,271 shares. This insider trade resulted in a net sale of 459 shares valued at approximately $36,357.
ANI Pharmaceuticals (ANIP) legal chief sells 500 shares under 10b5-1 plan
Meredith Cook, Senior VP, General Counsel, and Secretary of ANI Pharmaceuticals (ANIP), sold 500 shares of company common stock at $78.16 per share on May 13, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025. Following the sale, Cook directly holds 78,390 shares, maintaining a substantial equity position in the company.
ANI Pharmaceuticals projects ~$1.1B 2026 revenue; raises guidance, $100M buyback authorized
ANI Pharmaceuticals has updated its investor presentation, projecting approximately $1.1 billion in total net revenue for 2026 and raising its adjusted non-GAAP EBITDA guidance to $285 million–$300 million for the same year. The company expects its Rare Disease business to account for about 60% of 2026 revenues, primarily driven by Cortrophin Gel, with anticipated net revenue of $540 million–$575 million. Additionally, ANI Pharmaceuticals' board has authorized a new $100 million share repurchase program.
ANI Pharmaceuticals, Inc. $ANIP Shares Purchased by Vanguard Group Inc.
Vanguard Group Inc. increased its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 2.2% in the fourth quarter, bringing its total holdings to 1.31 million shares valued at $103 million. Other institutional investors also adjusted their positions, and the company reported strong Q4 earnings, surpassing analyst estimates with $2.05 EPS and $237.46 million in revenue. Analysts maintain a "Moderate Buy" rating with a consensus price target of $107.33, well above the current share price.
[144] ANI PHARMACEUTICALS INC SEC Filing
ANI Pharmaceuticals Inc. (ANIP) has filed a Rule 144 notice to sell 55,000 shares of common stock on Nasdaq, valued at $4,266,563.58. The filing details four planned issuances tied to performance shares and restricted stock from February and March 2026. This procedural notice indicates a planned resale but does not confirm execution timing or buyer identity.
Patrick Walsh plans sale of 3,973 ANIP shares (NASDAQ: ANIP)
Patrick Walsh has filed a Form 144 to sell 3,973 shares of ANIP (ANI Pharmaceuticals Inc.) common stock, identified as restricted stock granted on May 21, 2025. The filing also discloses a prior sale of 6,000 shares on March 3, 2026, for $445,390.20. A Form 144 signals an insider's intent to sell restricted securities, increasing transparency regarding potential stock market activities.
ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised
ANI Pharmaceuticals (ANIP) reported a strong first quarter in 2026, with adjusted EPS of $2.05 and revenues of $237.5 million, both surpassing analyst estimates. The company's performance was driven by significant growth in its Rare Disease and Brands segments, especially Purified Cortrophin Gel, and contributions from a new licensing agreement with Harmony Biosciences. Following these results, ANIP raised its full-year 2026 outlook for total net revenues and adjusted EBITDA, and authorized a new $100 million share repurchase program.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Recommendation of "Moderate Buy" by Brokerages
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has received a consensus "Moderate Buy" rating from brokerages, with an average 12-month price target of $107.33. This follows a strong quarterly earnings report where the company significantly beat EPS and revenue expectations and raised its FY 2026 EPS guidance, indicating confidence in future profitability. Insider selling has occurred, but institutional investors have largely increased their positions in the company.
ANI Pharmaceuticals (ANIP) shares jump after earnings beat and higher outlook
ANI Pharmaceuticals (ANIP) shares rose significantly after the company reported strong Q1 2024 earnings, surpassing analyst expectations for both revenue and EPS. The company also raised its full-year 2024 financial guidance, indicating continued positive momentum.
ANI Pharmaceuticals stock surges 10% on earnings beat, guidance raise
ANI Pharmaceuticals Inc. shares surged nearly 10% in pre-market trading after the company reported first-quarter results that significantly exceeded Wall Street expectations. The specialty pharmaceutical company beat adjusted EPS estimates by $0.60 and saw revenue increase by 20.5% year-over-year, driven by strong growth across all segments, especially its flagship Cortrophin Gel product. ANI Pharmaceuticals also raised its full-year 2026 revenue, adjusted EPS, and adjusted EBITDA guidance.
ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded by Wall Street Zen to Strong-Buy Rating
ANI Pharmaceuticals (NASDAQ:ANIP) received an upgrade from Wall Street Zen to a "strong-buy" rating, contributing to a "Moderate Buy" consensus among analysts with an average target price of $107.33. This upgrade follows the company's strong quarterly performance, where it exceeded EPS and revenue expectations. ANI Pharmaceuticals also raised its full-year 2026 EPS guidance, indicating management's confidence in continued profitability.
ANI Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
ANI Pharmaceuticals Inc has released its earnings summary for the quarter that concluded on March 31. The report contains financial results for the specified period. This brief article primarily serves as an announcement of the earnings report.
ANI Pharmaceuticals Q1 2026 EPS Beats Estimates; Revenue Up 20%
ANI Pharmaceuticals (NASDAQ:ANIP) reported impressive Q1 2026 results, with adjusted non-GAAP diluted EPS of $2.05, significantly beating estimates, and revenue up 20.5% year-over-year to $237.5M. The strong performance was primarily driven by its Rare Disease franchise, particularly Cortrophin Gel, which saw a 42.1% revenue increase. Despite the positive financial performance and ambitious FY26 guidance, the stock traded down 4.0%, suggesting market concerns potentially related to valuation or elevated expectations.
ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2026 Earnings Guidance
ANI Pharmaceuticals (NASDAQ:ANIP) has released its FY 2026 earnings guidance, projecting EPS between $9.19 and $9.69, surpassing the consensus, and revenue of $1.1 billion, meeting expectations. The company also reported strong Q1 results with EPS of $2.05 and revenue of $237.5 million, both exceeding analyst estimates. ANIP shares saw a rise in value and trading volume following these announcements, with analysts maintaining a "Moderate Buy" consensus.
ANI Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:ANIP) 2026-05-08
ANI Pharmaceuticals, Inc. (ANIP) released its Q1 2026 earnings, reporting an EPS of $2.05, which beat expectations by $0.75. The company's revenue reached $237.46M, an increase of 20.46% year-over-year, beating estimates by $29.83M. This article presents the slide deck from their earnings call.
ANI Pharmaceuticals Releases Q1 2026 Financial Results
ANI Pharmaceuticals reported strong Q1 2026 results, with adjusted diluted earnings per share of $2.05, significantly beating the Wall Street consensus. The company's revenue rose 20.5% to $237.5M, driven primarily by a 36.9% increase in its Rare Disease segment, with Cortrophin Gel contributing $75.1M. Management also provided optimistic full-year guidance for fiscal 2026 adjusted EPS.
Earnings call transcript: ANI Pharmaceuticals beats Q1 2026 expectations
ANI Pharmaceuticals (ANIP) significantly exceeded Q1 2026 expectations, reporting an EPS of $2.05 against a forecast of $1.45, and revenue of $237.5 million, surpassing the $213.42 million projection. The company saw a 4.81% rise in premarket trading and raised its full-year 2026 financial guidance, attributing strong growth to products like Cortrophin Gel and strategic initiatives in rare disease treatments. Executive commentary highlighted the success of their transformation strategy and commitment to growth, while also addressing challenges like increased SG&A expenses and insurance reverification delays.
ANI Pharmaceuticals, Inc. announces an Equity Buyback for $100 million worth of its shares.
ANI Pharmaceuticals, Inc. has announced a share repurchase program. The company plans to buy back $100 million worth of its shares using its cash resources. This program will be valid until May 2029.
ANI Pharmaceuticals (NASDAQ: ANIP) Q1 2026 revenue and earnings surge on Rare Disease growth
ANI Pharmaceuticals (NASDAQ: ANIP) reported strong Q1 2026 results, with net revenues increasing by 20.5% to $237.5 million and net income nearly doubling to $29.5 million, or $1.28 diluted EPS. This growth was primarily fueled by its Rare Disease and Brands segment, particularly Cortrophin Gel, and higher operating cash flow reflecting improved profitability. The company highlighted strategic initiatives in its Rare Disease segment, including expanded indications for ILUVIEN and building a dedicated sales force for acute gouty arthritis, while also focusing on niche opportunities in its Generics segment.
ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
ANI Pharmaceuticals reported strong first-quarter 2026 financial results, with net revenues of $237.5 million, up 20.5% year-over-year, and adjusted non-GAAP EBITDA of $63.0 million, a 24.1% increase. The company raised its full-year 2026 financial guidance, now expecting total net revenues between $1,080 million and $1,140 million, and authorized a $100 million share repurchase program. This performance was driven by significant growth in its Rare Disease segment, particularly Cortrophin Gel, and solid contributions from its Generics business.
ANI: Q1 Earnings Snapshot
ANI Pharmaceuticals Inc. (ANIP) reported a first-quarter profit of $29.5 million, or $1.28 per share, which adjusted to $2.05 per share, surpassing analyst expectations. The drugmaker also exceeded revenue forecasts with $237.5 million for the period and provided full-year earnings and revenue guidance. The company's shares have shown modest growth year-to-date and significant growth over the past year.
ANI: Q1 Earnings Snapshot
ANI Pharmaceuticals Inc. reported a strong first quarter, with profit reaching $29.5 million and diluted earnings per share of $1.28, significantly beating Wall Street expectations. The company also surpassed revenue forecasts, posting $237.5 million. ANI provided optimistic full-year guidance for both earnings and revenue, and its stock has shown year-to-date and 12-month gains.
Are Estimate Revisions Reshaping ANI Pharmaceuticals' (ANIP) Earnings Narrative After Its Q1 2026 Call?
ANI Pharmaceuticals (ANIP) recently reported its Q1 2026 earnings, with analysts expecting US$1.28 EPS and modest revenue growth. The company reaffirmed its full-year 2026 revenue guidance of US$1,055 million to US$1,115 million, highlighting the role of recent generic product launches. However, investor sentiment is also influenced by potential payer pushback on high-cost rare disease drugs like Cortrophin Gel, contributing to a diverse range of fair value estimates for the stock.
ANI Pharmaceuticals set to report earnings amid estimate cuts
ANI Pharmaceuticals is expected to report its first-quarter earnings, with analysts anticipating a decline in EPS and revenue from the previous quarter, despite a year-over-year revenue increase. Wall Street has lowered expectations, but analysts generally remain bullish on the stock, with predictions of over 31% upside. Investors will be focused on the performance of Cortrophin Gel, management's guidance, and the progression of the company's high-margin rare disease business.
ANI Pharmaceuticals (Nasdaq:ANIP) - Stock Analysis
ANI Pharmaceuticals (ANIP) is a biopharmaceutical company trading at a significant discount to its fair value, with analysts forecasting a 24.82% annual growth in earnings. The company recently became profitable and has received positive analyst consensus, despite some recent insider selling and a high level of debt. Recent developments include increased earnings guidance for 2026, a $100 million share repurchase program, and the launch of several generic pharmaceutical products.
Hussman Strategic Advisors Inc. Takes Position in ANI Pharmaceuticals, Inc. $ANIP
Hussman Strategic Advisors Inc. initiated a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the fourth quarter, acquiring 31,500 shares valued at approximately $2.49 million. Several other institutional investors, including Arrowstreet Capital, Balyasny Asset Management, and UBS Group AG, also significantly increased their positions in ANIP, contributing to a 76.05% institutional ownership. Despite insiders selling about 27,860 shares valued at approximately $2.11 million in the last 90 days, analysts maintain a "Moderate Buy" rating with an average price target of $107.33.
Artemis Investment Management LLP Invests $1.71 Million in ANI Pharmaceuticals, Inc. $ANIP
Artemis Investment Management LLP has acquired a new stake of 21,617 shares in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), valued at approximately $1.71 million. This new investment represents about 0.10% ownership, contributing to the 76.05% of ANIP stock held by institutional investors and hedge funds. Wall Street analysts maintain a "Moderate Buy" rating for ANIP, with an average price target of $107.33, while the company's stock currently trades around $80.
ANI Pharmaceuticals (ANIP) Announces Launch of Pimozide Tablets 1 mg and 2 mg
ANI Pharmaceuticals (NASDAQ:ANIP) has announced the launch of Pimozide Tablets 1 mg and 2 mg, a generic version of Orap®, with reported US annual sales of $3.1 million. This follows their earlier launch of Carbamazepine Extended-Release Capsules, which generated $65 million in US annual sales. The company aims to provide limited competition products and generic alternatives to patients and customers.
ANI Pharmaceuticals (ANIP) Expected to Announce Earnings on Friday
ANI Pharmaceuticals (ANIP) is scheduled to announce its Q1 2026 earnings before market open on Friday, May 8th, with analysts projecting $1.28 EPS and $207.63 million in revenue. Wall Street maintains a "Moderate Buy" rating with an average price target of $107.33, following recent analyst upgrades. The stock opened at $79.45, while insider selling and institutional investor activity have also been noted.
9 Best Drug Stocks to Buy According to Analysts
This article identifies ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) as one of the top drug stocks recommended by analysts. It highlights the company's recent launch of generic versions of Pimozide Tablets and Carbamazepine Extended-Release Capsules, noting their respective annual sales of $3.1 million and $65 million based on February 2026 IQVIA data. ANI Pharmaceuticals, a bio-pharmaceutical company, specializes in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals across different segments.
9 Best Drug Stocks to Buy According to Analysts
This article identifies ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) as one of the best drug stocks to buy, according to analysts. It highlights the company's recent launches of generic Pimozide Tablets and Carbamazepine Extended-Release Capsules, detailing their market potential based on US annual sales data. ANI Pharmaceuticals focuses on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals across various market segments.
ANI Pharmaceuticals rolls out generic carbamazepine extended-release capsules
ANI Pharmaceuticals has launched a generic version of carbamazepine extended-release capsules, indicated for treating seizures and neuropathic pain. This new generic drug is available in 100 mg, 200 mg, and 300 mg strengths. The company anticipates an addressable market of approximately $36 million for these capsules.
What ANI Pharmaceuticals (ANIP)'s Niche CNS Generic Launches Mean For Its Specialty-First Strategy
ANI Pharmaceuticals recently launched Pimozide Tablets and Carbamazepine Extended Release Capsules, expanding its generic portfolio. While these launches are expected to modestly broaden revenue, the company's investment narrative remains centered on the performance of Cortrophin Gel and the balance between rare disease and generic franchises. Upcoming Q1 2026 results will provide further insight into the contribution of these new generics and their alignment with ANI's projected $1.055 billion to $1.115 billion revenue guidance for 2026.
ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced it will release its first quarter 2026 financial results on Friday, May 8, 2026, before the market opens. A webcast and conference call will be hosted by CEO Nikhil Lalwani, SVP Finance Stephen P. Carey, and Head of Rare Disease Chris Mutz to discuss the results. The event details and a replay will be available on the company's website.
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Passes Below 200-Day Moving Average - Here's Why
ANI Pharmaceuticals (NASDAQ:ANIP) stock has fallen below its 200-day moving average, trading as low as $76.84, which signals potential technical weakness. Despite this, Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $107.33, and some have recently upgraded their targets. However, company insiders have been net sellers in the past quarter, selling 27,860 shares valued at approximately $2.11 million.
ANIP Price Today: ANI Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC
This page from MEXC Exchange provides current pricing, quotes, and charts for ANI Pharmaceuticals, Inc. (ANIP) stock. It positions MEXC as a fee-free platform for trading various cryptocurrencies, including Bitcoin and Ethereum.
ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced it will release its first quarter 2026 financial results on Friday, May 8, 2026, before market open. The company's leadership, including President and CEO Nikhil Lalwani, will host a webcast and conference call to discuss these results. Details for accessing the webcast and replay can be found on ANI Pharmaceuticals' investor relations website.
